Wolfe Josh
SEC Form 4 insider trading activity
Wolfe Josh has filed 1 SEC Form 4 filing (5 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 6, 2026.
On the most recent filing, Wolfe Josh is listed as Director, 10% Owner at Eikon Therapeutics, Inc. Inside the rolling window, Wolfe Josh reported 1 open-market purchase totaling $2.5M in EIKN and no open-market sales.
Companies traded
Other insiders at EIKN
Insider Buying
$2.5M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Wolfe Josh made?
Wolfe Josh has filed 1 SEC Form 4 filing (5 transaction rows) across 1 company since 2026.
Which companies does Wolfe Josh trade?
Wolfe Josh has filed SEC Form 4 disclosures for 1 company, including EIKN.
When was Wolfe Josh's most recent SEC Form 4 filing?
Wolfe Josh's most recent SEC Form 4 filing on Tracefour is dated Feb 6, 2026.
What is Wolfe Josh's total buy and sell value in the current window?
Inside the rolling retention window, Wolfe Josh bought $2.5M and sold $0 based on SEC Form 4 filings.
What was Wolfe Josh's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 138,888 EIKN shares on 2026-02-04, worth $2.5M, per SEC Form 4 filings.